Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NRSN

NeuroSense Therapeutics Ltd

Dec 13 • 04:00PM ET

0.8600

Dollar change -0.0700
Percentage change -7.53	%

Healthcare • Biotechnology • Israel • NASD

Peers: BIIB LLY REGN VRTX GILD AMGN BGNE ALNY MRNA NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	23.78%	Shs Outstand	18.06M	Perf Week	-17.31%
Market Cap	16.47M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	15.79M	Perf Month	-35.34%
Income	-8.43M	PEG	-	EPS next Q	-0.08	Inst Own	1.09%	Short Float	2.05%	Perf Quarter	-35.82%
Sales	0.00M	P/S	-	EPS this Y	33.73%	Inst Trans	-85.33%	Short Ratio	1.65	Perf Half Y	-11.34%
Book/sh	-0.09	P/B	-	EPS next Y	25.45%	ROA	-173.59%	Short Interest	0.32M	Perf Year	26.47%
Cash/sh	0.06	P/C	13.28	EPS next 5Y	-	ROE	-602.40%	52W Range	0.51 - 2.33	Perf YTD	9.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.06%	ROI	-	52W High	-63.09%	Beta	1.37
Dividend TTM	-	Quick Ratio	0.46	Sales past 5Y	0.00%	Gross Margin	-	52W Low	67.97%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	0.46	EPS Y/Y TTM	56.97%	Oper. Margin	-	RSI (14)	32.91	Volatility	11.67% 11.73%
Employees	18	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	87.61%	Payout	-	Rel Volume	1.41	Prev Close	0.93
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	196.90K	Price	0.86
SMA20	-14.69%	SMA50	-24.13%	SMA200	-27.22%	Trades		Volume	277,599	Change	-7.53%

Dec-11-24 09:25AM	NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) -10.76%
Dec-04-24 08:30AM	NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS (PR Newswire) -5.31%
Dec-02-24 08:30AM	NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price (PR Newswire) +14.27%
Nov-21-24 09:20AM	NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND (PR Newswire) -7.08%
Oct-28-24 08:30AM	NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission (PR Newswire) +6.30%
08:30AM	Loading…
Oct-24-24 08:30AM	New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients (PR Newswire) +5.22%
Oct-15-24 09:15AM	NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates (PR Newswire) -12.20%
Oct-09-24 09:00AM	NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada (PR Newswire)
Oct-07-24 09:00AM	NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting (PR Newswire)
Sep-24-24 09:05AM	NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's (PR Newswire)
09:00AM	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule (PR Newswire)
Aug-30-24 04:30PM	NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire) +17.11% +10.09%
Aug-07-24 02:00PM	NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price (PR Newswire)
Aug-01-24 09:15AM	NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial (PR Newswire) -10.50%
Jul-09-24 09:27AM	NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression (PR Newswire) -19.11%
08:00AM	Loading…
Jul-01-24 08:00AM	NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug (PR Newswire)
Jun-24-24 02:52PM	NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.87%
09:00AM	NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results (PR Newswire)
Jun-21-24 04:30PM	NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal (PR Newswire)
May-20-24 09:00AM	NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit (PR Newswire)
May-14-24 09:05AM	NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning (PR Newswire)
May-07-24 08:45AM	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients (PR Newswire)
May-02-24 09:19AM	NeuroSense Announces First Quarter 2024 Business Update (PR Newswire)
Apr-22-24 08:30AM	NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease (PR Newswire)
Apr-18-24 08:30AM	NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting (PR Newswire) -5.00%
Apr-12-24 08:30AM	NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 (PR Newswire)
Apr-10-24 07:16PM	NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Apr-09-24 08:30AM	NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics (PR Newswire)
Apr-05-24 08:52PM	NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -17.48%
09:29AM	NeuroSense Announces Year End 2023 Financial Results and Provides Business Update (PR Newswire)
08:30AM	Loading…
Feb-21-24 08:30AM	NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial (PR Newswire) -8.76%
Feb-07-24 09:27AM	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule (PR Newswire)
Jan-30-24 08:30AM	NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 (ACCESSWIRE)
Jan-09-24 08:45AM	NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts (PR Newswire)
Dec-27-23 05:00PM	NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (PR Newswire)
Dec-14-23 09:24AM	NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial (PR Newswire) +27.93%
Dec-05-23 08:00AM	NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints (PR Newswire) -24.16%
Dec-04-23 04:01PM	NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023 (PR Newswire) +15.50%
Nov-28-23 08:45AM	NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire) +5.83%
Nov-13-23 09:20AM	NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness (PR Newswire)
Nov-09-23 09:00AM	NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences (PR Newswire)
Nov-06-23 08:30AM	NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 (PR Newswire) +12.93%
Nov-01-23 09:00AM	NeuroSense Therapeutics to Participate in BIO-Europe Fall (PR Newswire)
Oct-19-23 10:30AM	Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics Lead Drug Candidate, PrimeC (ACCESSWIRE)
Oct-17-23 08:30AM	NeuroSense CEO Provides Q3 2023 Update (PR Newswire)
Oct-04-23 09:10AM	NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model (PR Newswire) -7.91%
07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Oct-02-23 08:46AM	NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results (PR Newswire)
Sep-20-23 09:05AM	European Medicines Agency Grants NeuroSense SME Status (PR Newswire)
Sep-19-23 09:00AM	NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC (PR Newswire)
Sep-14-23 09:00AM	NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S. (PR Newswire)
Sep-06-23 08:30AM	NeuroSense to Host Investor Webinar on September 12, 2023 (PR Newswire)
Aug-16-23 09:00AM	NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -5.23%
Jul-17-23 08:30AM	NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023 (PR Newswire)
Jul-11-23 09:00AM	NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit (PR Newswire)
Jul-06-23 08:30AM	NeuroSense CEO Provides Q2 2023 Update (PR Newswire)
Jun-22-23 08:30AM	NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Jun-01-23 08:45AM	NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023 (PR Newswire)
May-15-23 09:05AM	NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial (PR Newswire)
May-02-23 08:30AM	NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study (PR Newswire) -20.10%
Apr-17-23 09:05AM	NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment (PR Newswire)
Mar-27-23 09:15AM	NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS (PR Newswire)
Mar-23-23 09:05AM	NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD 2023 Advances in Science & Therapy Conference (PR Newswire)
Mar-22-23 08:45AM	NeuroSense Announces Year End 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-16-23 08:30AM	NeuroSense Therapeutics to Participate in BIO-Europe Spring (PR Newswire)
Mar-14-23 08:40AM	NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023 (PR Newswire)
Feb-13-23 08:30AM	NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts (PR Newswire)
Feb-10-23 05:45AM	Here's Why We're Watching NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Situation (Simply Wall St.)
Feb-09-23 09:20AM	NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases (PR Newswire) +13.16%
Feb-08-23 09:14AM	NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial (PR Newswire)
Feb-06-23 09:12AM	NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study (PR Newswire)
Jan-19-23 08:52AM	NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study (PR Newswire) +76.19%
Dec-01-22 09:05AM	NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Nov-16-22 09:34AM	NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS (PR Newswire) +5.92%
Nov-15-22 08:30AM	NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study (PR Newswire) +7.94%
Oct-27-22 08:50AM	NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences (PR Newswire) -8.02%
Oct-21-22 09:25AM	NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany (PR Newswire)
Oct-18-22 08:30AM	NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video (PR Newswire)
Oct-12-22 08:30AM	NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City (PR Newswire) +12.03%
Sep-29-22 08:30AM	NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference (PR Newswire)
Sep-28-22 08:30AM	NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US (PR Newswire) +7.78%
Sep-21-22 08:51AM	NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences (PR Newswire)
Sep-20-22 08:45AM	NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial (PR Newswire)
Sep-19-22 09:14AM	NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (PR Newswire)
Aug-31-22 09:00AM	NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Aug-29-22 02:02PM	NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-02-22 08:30AM	NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study (PR Newswire)
Jul-28-22 09:00AM	NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML (PR Newswire)
Jul-18-22 08:30AM	NeuroSense Therapeutics CEO Provides Key Corporate Update Video (PR Newswire)
Jun-30-22 09:05AM	NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study (Benzinga) +23.36%
08:30AM	NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study (PR Newswire)
Jun-27-22 08:30AM	NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study (PR Newswire) +47.06%
Jun-22-22 08:30AM	NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022 (PR Newswire)
Jun-01-22 08:30AM	NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC (PR Newswire)
May-31-22 08:30AM	NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update (PR Newswire) -5.37%
May-23-22 08:30AM	NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022 (PR Newswire)
Apr-11-22 08:30AM	NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS (PR Newswire) -15.55%
Apr-06-22 08:30AM	NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC (PR Newswire) -9.19%
Mar-30-22 08:15AM	NeuroSense Therapeutics CEO Provides Key Corporate Update Video (PR Newswire) -11.80%

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer's and Parkinson's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRSN

NeuroSense Therapeutics Ltd

Upgrade your FINVIZ experience